IMNM - NASDAQ
Immunome, Inc.
$19.78
-0.15%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live SnapshotImmunome, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Immunome, Inc. Income Statement
IMNM • NASDAQ
| Immunome, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
6.9M | 9M | 14M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(3M) | (0.0) | (0.0) | (0.0) | (0.0) | (755K) | (615K) | (521K) | |
4M | 9M | 14M | 0.0 | 0.0 | -755K | -615K | -521K | |
OPERATING INCOME | ||||||||
(218.1M) | (314.8M) | (123.5M) | (36.9M) | (25.2M) | (11.5M) | (10.3M) | (7.7M) | |
(43.8M) | (33M) | (19.7M) | (13.6M) | (11.1M) | (4.8M) | (1.5M) | (866K) | |
(174.3M) | (129.5M) | (23.1M) | (23.3M) | (14.1M) | (6.7M) | (8.8M) | (6.9M) | |
-214.1M | -305.8M | -109.5M | -36.9M | -25.2M | -12.3M | -10.3M | -7.7M | |
PRE-TAX INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (5K) | (10K) | (38K) | (106K) | (141K) | |
11.7M | 12.8M | 2.7M | 0.0 | 0.0 | -37K | -96K | -102K | |
(0.0) | (152.3M) | (80.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.7M | 12.8M | 2.7M | 5K | 493K | -5.6M | -96K | -102K | |
-212.4M | -293M | -106.8M | -36.9M | -24.7M | -17.8M | -10.4M | -7.8M | |
NET INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (39K) | |
-212.4M | -293M | -106.8M | -36.9M | -24.7M | -17.8M | -10.6M | -7.8M |
SEC Filings
IMNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 |
Related Guides
Continue your IMNM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.